Scientists are supercharging patients' own immune cells to try to fight HIV without today's drugs. A small study is giving a ...

By Deena Beasley May 11 (Reuters) - Re-engineering an HIV patient's own immune cells to find and destroy the virus succeeded ...

Engineered CAR‑T cells suppressed HIV off medication in two people — promising but early. Larger trials are needed.

Members of the CAR T Vision Steering Committee outline key issues around US and EU reimbursement and discuss potential solutions Am J Manag Care. 2025;31(Spec. No. 13 ...

A detailed analysis of T-cell redirecting therapies in oncology, comparing the mechanisms of bispecific antibodies and CAR T cells.

In this retrospective analysis, researchers used real-world data to investigate sex-associated differences in CAR T-cell therapy-related toxicity.

Developing effective immunotherapies for acute myeloid leukemia (AML) has long been hampered by a critical challenge: Therapy directed at killing the leukemia cells may also harm the body's ability to ...

During a live event, Binod Dhakal, MD, discussed the evidence for targeting XPO1 and GPRC5D before BCMA CAR T-cell therapy in multiple myeloma.

This review examines how CAR-T cell therapy is expanding beyond blood cancers into solid tumors, autoimmune diseases, chronic viral infections, and next-generation immune-cell platforms. It highlights ...

Soficabtagene geleucel (WU-CART-007) received FDA Breakthrough Therapy Designation for treating relapsed or refractory T-cell leukemia and lymphoma. The CRISPR-engineered treatment achieved a 91% ...

Please provide your email address to receive an email when new articles are posted on . Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly ...